Neurofilament heavy chain and chitinase 3-like 1 as markers for monitoring therapeutic response in multiple sclerosis
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, pozorovací studie
PubMed
39383686
DOI
10.1016/j.msard.2024.105915
PII: S2211-0348(24)00491-7
Knihovny.cz E-zdroje
- Klíčová slova
- Chitinase 3-like 1, ELISA, Multiple sclerosis, Neurofilament heavy chain,
- MeSH
- biologické markery * krev MeSH
- dospělí MeSH
- hodnocení výsledků zdravotní péče MeSH
- imunologické faktory aplikace a dávkování farmakologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- neurofilamentové proteiny * krev MeSH
- prospektivní studie MeSH
- protein CHI3L1 * krev MeSH
- roztroušená skleróza krev farmakoterapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- pozorovací studie MeSH
- Názvy látek
- biologické markery * MeSH
- CHI3L1 protein, human MeSH Prohlížeč
- imunologické faktory MeSH
- neurofilament protein H MeSH Prohlížeč
- neurofilamentové proteiny * MeSH
- protein CHI3L1 * MeSH
AIMS: The aim of this study was to evaluate the association of serum neurofilament heavy chain (sNfH) and chitinase 3-like 1 (sCHI3L1) with treatment response and disease activity in multiple sclerosis (MS). METHODS: This single-center, prospective, observational cohort study was conducted at the MS Centre, University Hospital Ostrava, Czech Republic, from May 2020 to August 2023. sNfH and sCHI3L1 were determined using ELISA. A mixed-effects linear model with a log-transformed outcome variable was applied. RESULTS: We analyzed 459 samples from 57 people with MS. Patients were sampled an average of 8.05 times during 21.9 months of follow-up. Those experiencing a relapse at sampling had a sNfH concentration 50 % higher than those in remission (exp(β) 1.5, 95 % CI 1.15-1.96). A longer duration of treatment was associated with lower sNfH (exp(β) 0.95, 95 % CI 0.94-0.96). Patients switched from low- to high-efficacy disease-modifying therapies (DMTs) had higher sNfH than patients treated with low-efficacy DMTs only (exp(β) 1.95, 95 % CI 1.35-2.81). Higher sCHI3L1 was associated with older age (exp(β) 1.01, 95 % CI 1.00-1.02) and longer DMT use (exp(β) 1.01, 95 % CI 1.00-1.02). sCHI3L1 values were not associated with relapse at the time of sampling, renal function, sex, or type of DMT. CONCLUSION: In contrast to sCHI3L1, sNfH may be a potential biomarker for monitoring treatment response and confirming clinical relapse in MS. Further research is needed to determine the long-term dynamics of sNfH and develop related treatment strategies.
University Hospital Ostrava Department of Hematooncology Ostrava Czech Republic
University of Ostrava Department of Clinical Neurosciences Ostrava Czech Republic
Citace poskytuje Crossref.org
